← All drugs Report issue

anti cd45 monoclonal antibody

mAbexperimental

Clinical trial activity

10 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

10

Phase 2

4

Phase 3

0

Phase 4

0

Earliest trial started Jul 1, 2001 (NCT00590460)

Timeline

2000s

Jan 1, 2001
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Leukocyte common antigenINHIBITOR
PTPRC inhibitor
- Receptor-type tyrosine-protein phosphatase C (PTPRC) ↗

Chemistry & pharmacology

Multi-specific: No

Oral

No

Parenteral

No

Topical

No

Also known as

anti-cd45
anti cd45 monoclonal antibody
cd45 antibodies
cd45 mab

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00706316	Phase 1	Dec 1, 2007	University of Toronto
NCT00579137	Phase 1/Phase 2 (Phase 2)	Oct 1, 2007	Baylor University
NCT00515957	Phase 1	Aug 1, 2007	Baylor University, Methodist Cancer Center, Houston, Texas
NCT00082225	Phase 1	Oct 1, 2003	Baylor University, Methodist Cancer Center, Houston, Texas
NCT00078546	Phase 1	Sep 1, 2003	Baylor University, Methodist Cancer Center, Houston, Texas
NCT00057005	Phase 1	Feb 1, 2003	Baylor University, Methodist Cancer Center, Houston, Texas
NCT00056966	Phase 1/Phase 2 (Phase 2)	Nov 1, 2002	Baylor University, Methodist Cancer Center, Houston, Texas
NCT00056979	Phase 1/Phase 2 (Phase 2)	Jun 1, 2002	Baylor University, Methodist Cancer Center, Houston, Texas
NCT00586274	Phase 1	Mar 1, 2002	Baylor University, The University of Texas, Dallas
NCT00590460	Phase 1/Phase 2 (Phase 2)	Jul 1, 2001	Baylor University, Methodist Cancer Center, Houston, Texas

Showing 10 of 10 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Baylor University	Academic/Hospital	9	9	2	2001
Methodist Cancer Center, Houston, Texas	Academic/Hospital	7	0	2	2001
The University of Texas, Dallas	Academic/Hospital	1	0	1	2002
University of Toronto	Academic/Hospital	1	1	1	2007

4 organizations

Page 1 / 1